Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | STS | P08842 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806082 | 1.00 | HSD11B1 (0.78) | HSD11B1MAPTCYP3A4STSCA1 | |
| SCHEMBL3649589 | 1.00 | HSD11B1 (0.78) | HSD11B1MAPTCYP3A4STSCA1 | |
| SCHEMBL796274 | 0.89 | HSD11B1 (0.61) | HSD11B1MAPTCYP3A4STSCA1 | |
| SCHEMBL13268578 | 0.88 | HSD11B1 (1.00) | HSD11B1MAPTCYP3A4STSESR1 | |
| SCHEMBL4590174 | 0.85 | HSD11B1 (0.64) | HSD11B1MAPTCYP3A4STSCA1 | |
| SCHEMBL11877226 | 0.84 | HSD11B1 (0.56) | HSD11B1MAPTCYP3A4STSCA1 | |
| SCHEMBL12696810 | 0.84 | HSD11B1 (0.56) | HSD11B1MAPTCYP3A4STSCA1 | |
| SCHEMBL22267490 | 0.84 | HSD11B1 (0.56) | HSD11B1MAPTCYP3A4STSCA1 | |
| SCHEMBL10619181 | 0.84 | HSD11B1 (0.76) | HSD11B1MAPTCYP3A4STSESR1 | |
| SCHEMBL4587946 | 0.84 | HSD11B1 (0.71) | HSD11B1MAPTSTSESR1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024568-A1 | METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES | ENDECE LLC | 2021-01-28 | — | — | US | disclosed |
| US-10723757-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190135853-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | ENDECE LLC | 2019-05-09 | — | — | US | disclosed |
| US-10174070-B2 | 6-substituted estradiol derivatives and methods of use | ENDECE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-9636348-B2 | 6-substituted estradiol derivatives for use in remyelination of nerve axons | ENDECE LLC (US) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723757-B2 | 6-substituted estradiol derivatives and methods of use | SHBG, HSD17B11, CYP19A1 | HSD11B1 55/4885MAPT 255/4885CYP3A4 64/4885 |
| US-20190135853-A1 | 6-Substituted Estradiol Derivatives and Methods of Use | SHBG, HSD17B11, CYP19A1 | HSD11B1 55/4885MAPT 255/4885CYP3A4 64/4885 |
| US-10174070-B2 | 6-substituted estradiol derivatives and methods of use | NR3C2, SHBG, NR5A1 | HSD11B1 46/4885MAPT 2929/4885CYP3A4 587/4885 |
| US-20210024568-A1 | METHODS FOR MODULATION OF LIPOPROTEIN LIPASE AND APOLIPOPROTEIN C2 EXPRESSION AND/OR ACTIVITY IN THE TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM TISSUE DISEASE STATES | LPL, LIPE, PMP22 | HSD11B1 594/4885MAPT 2201/4885CYP3A4 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.